SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure amid broader market volatility, with the community actively debating whether the stock is a long-term value opportunity or a sinking asset due to execution risks and high valuation concerns. Investors are closely monitoring the stock's technical support levels as bearish sentiment surges over delivery performance and potential capital rotation into other ventures.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is experiencing significant volatility and fragmented sentiment as market participants brace for an upcoming press conference regarding geopolitical tensions and the conflict with Iran. The community is actively debating the reliability of ceasefire rumors while monitoring price action for signs of an institutional 'rug pull' or potential market-moving headlines.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Invesco QQQ Trust is experiencing heavy volatility as investors weigh conflicting reports of ceasefire negotiations against ongoing military tensions in the Middle East, leading to intense debate among market participants about whether current price action reflects genuine growth or orchestrated market manipulation. The community is actively parsing news regarding geopolitical deadlines and oil price shifts while attempting to navigate algorithmic swings driven by uncertainty.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a surge in investor confidence driven by the strategic $14.2 billion buyout of its Ireland Fab 34 joint venture, which analysts view as a major step toward reclaiming manufacturing control and long-term margin growth. The community is actively debating the stock's potential for a sustained breakout, with many traders pointing to strong demand for server CPUs and AI-focused infrastructure as catalysts for further upside.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense volatility and aggressive trading as investors debate whether recent price action is a fundamental valuation correction driven by AI-related substrate demand or a speculative bubble prone to a sharp reversal. The community remains deeply divided, with many traders monitoring for a potential dilution event while others emphasize the company's critical role in the photonics supply chain.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited ($MGRT) is trending as retail traders monitor its volatile price action and frequent trading halts, often comparing its movement to other low-float Chinese IPOs. The community remains deeply divided, with some betting on a potential squeeze and parabolic gains, while many others warn of a typical 'pump and dump' scam that frequently characterizes similar recent market entrants.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

Buttcoin

Buttcoin is gaining attention as a long-standing meme project, with the community actively debating whether its 15-year history of mocking the crypto industry translates into lasting value or a satirical phenomenon. Supporters are pushing the asset as a nostalgic, culture-driven alternative to mainstream tokens, while others view the surrounding social media fervor as a cautionary example of speculative retail behavior.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as investors debate the company's ability to overcome manufacturing hurdles at its Malaysia facility, specifically relating to laser dicing and production yields. While the community remains polarized between those viewing the stock as a distressed 'zombie' play and long-term believers citing institutional ownership and potential partnerships, high short interest and anticipation of upcoming purchase orders keep sentiment highly volatile.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as investors cheer the company's strategic pivot into AI infrastructure and recent high-profile production orders for its ultra-high-power testing systems. The community is heavily focused on the company's role as a critical bottleneck gatekeeper for reliability in the hyperscale data center supply chain, fueling bullish sentiment around upcoming earnings and guidance.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X ETF

Direxion Daily TSLA Bull 2X Shares

Direxion Daily TSLA Bull 2X Shares is trending as traders debate the impact of potential reverse splits and dividend distributions on this leveraged ETF amid Tesla's volatile price action. The community remains sharply divided, with some actively adding to positions hoping for a rebound toward previous highs while others emphasize the risks of volatility decay and institutional manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 39.8% in March

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest...

ProShares Ultra Nasdaq Biotechnology Declares Quarterly Dividend of $0.01 (NASDAQ:BIB)

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) announced a quarterly dividend on Tuesday, March 24th. Shareholders of record on Wednesday, March 25th will be given a dividend of 0.0071 per share...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average - What's Next?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Below 50 Day Moving Average - Time to Sell...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Below 50 Day Moving Average - Time to Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Cross Below 50-Day Moving Average - Here's Why...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 27.9% in January

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 21,087...

Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Declines By 29.2%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 28,385...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) to Issue Quarterly Dividend of $0.13

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) declared a quarterly dividend on Tuesday, December 23rd. Shareholders of record on Wednesday, December 24th will be paid a dividend of 0.1346 per...

<ul class="summary-bullets"><li>With Abivax now trading as a strategic asset rather than a pure clinical story, takeover interest from a deep-pocketed pharma player introduces a potential valuation floor.</li><li>At roughly an $11 billion market cap, the stock is priced with strong odds of UC success and meaningful commercialization.</li><li>There is still room for upside if Crohn’s disease data validate a broader, multi-indication franchise.</li></ul>French clinical-stage biotech Abivax (ABVX) had an uneventful Nasdaq debut in October 2023 and spent much of its early public life flying under the radar. That changed abruptly this year after a single clinical data readout flipped the narrative — a familiar inflection point in biotech investing.&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax’s stock</a> is up nearly 1,900% year-to-date, making it the best-performing biotech stock&nbsp;on U.S. exchanges.Adding fuel to the mid-year momentum, Eli Lilly (LLY) has emerged as a potential suitor, with market chatter suggesting the pharma giant is circling the smaller biotech. French media outlet La Lettre reported earlier this week that a delegation of Lilly executives met with the French Treasury and&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.lalettre.fr/fr/entreprises_sante/2025/12/22/l-americain-eli-lilly-en-operation-seduction-a-bercy-pour-racheter-la-biotech-abivax,110583257-art">submitted</a> an acquisition proposal for Abivax.How does this shift the investment thesis around this smaller name? What was once a high-beta, data-driven clinical bet increasingly looks like a strategic M&amp;A optionality trade, with a potential floor under the stock—at least in the near term.<img src="https://news.stocktwits-cdn.com/Abivax_since_IPO_png_b0a5af2a71.webp" alt="Abivax since IPO.png">Source: Koyfin<h2 class="st-heading-2">From Clinical Breakout to Strategic Asset</h2>For all the hype around the name, Abivax is still&nbsp;more or less a one-trick pony. Its lone pipeline asset and lead candidate, Obefazimod, is an immunomodulator that is being evaluated for multiple indications. The indication that is&nbsp;most developed is moderately to severely active ulcerative colitis (UC).&nbsp;Obefazimod acts by enhancing the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Inflammatory Bowel Disease (IBD), a broader term used to refer to chronic conditions such as UC and Crohn’s disease, is an autoimmune response. The immune system mistakenly attacks the gut, causing inflammation and damage to the digestive tract, leading to symptoms such as diarrhea, abdominal pain, weight loss and fatigue.&nbsp;UC affects the large intestine and rectum, causing ulcers on the inner lining, and Crohn’s disease can affect any part of the gastrointestinal tract and inflames the entire bowel wall.&nbsp;Is the condition such a big opportunity? By Abivax’s own account, it seems so. In a corporate presentation, the company said, citing Evaluate data, that IBD prevalence was 3.6 million in the G7 nations in 2024, with roughly 64% in the U.S. The prevalence is expected to grow at a modest 4% pace over the next six years. Worldwide IBD drug sales in 2024 are estimated at $23.7 billion, with 70% from the U.S.<h4 class="st-heading-4" style="text-align:center;">Worldwide IBD Sales&nbsp;</h4><figure class="image"><img style="aspect-ratio:661/535;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_1_48_03_AM_png_2f93920926.webp" alt="Screenshot 2025-12-24 at 1.48.03 AM.png" width="661" height="535"></figure>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Source: AbivaxThe current treatment options include:-Interleukin-23 selective inhibitors (block the action of pro-inflammatory cytokine protein interleukin-23)-Sphingosine 1-phosphate (S1P) modulators such as ozanimod and etrasimod (target proteins linked to inflammation on immune cells and stop them from leaving the lymph nodes)-Janus Kinase (JAK) inhibitors (stop several types of pro-inflammatory cytokines from forming)Abivax projects Obefazimod as a differentiated treatment option compared to existing therapies, by enhancing the expression of microRNA-124, a natural regulator of the inflammatory response. The mode of administration is also convenient: an oral once-daily pill with a favorable long-term safety profile.<h2 class="st-heading-2">Wall Street Analysts’ Optimism Abounds</h2>Following topline data from two Phase 3 studies showing the candidate met the primary and secondary endpoints, Abivax stock received love from several Wall Street firms, with Morgan Stanley upgrading the stock to an ‘Overweight,’ according to the Fly.&nbsp;The pooled placebo-adjusted clinical remission for the 50mg dose of 16.4% came in above the roughly 15% bar that Morgan Stanley analysts estimated based on their conversations with investors and experts. The analyst also expected improved odds of success across UC and Crohn's.&nbsp; Guggenheim analysts estimated Obefazimod’s value at $7 billion to $10 billion.Piper Sandler analysts said following the Phase 3 data, they have layered in revenue in early-line UC. This doubles its U.S. UC estimate to 2.66 billion euros ($3.14 billion) in 2035, suggesting there could be significant upside to the stock ahead of key data events.Abivax presented the results of the two late-stage studies at the United European Gastroenterology (UEG) Meeting in Berlin in early October. Citizen JMP analysts, who upped their price target ahead of the event, said the data reinforce Obefazimod’s efficacy and increase conviction in its multi-billion-dollar sales potential. Guggenheim named Abivax as a “Best Idea” and upped its price target to $150.&nbsp;Last month, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $176 price target. The firm based its optimistic assessment on its belief that the company’s odds of success in Crohn’s disease may be higher than those of UC. Crohn’s readout would be a better catalyst in 2026, it added.According to Koyfin, the average analyst price target for Abivax stock is $138.35, implying a 22% downside from current levels. Of the five analysts covering the stock, four have either a ‘Buy’ or a ‘Strong Buy’ rating, and one remains on the sidelines.<h2 class="st-heading-2">Retail Jump Onto Bullish Bandwagon</h2>The Abivax stock stream on Stocktwits has attracted a large following, with the watcher count jumping over 5,500% in the past year. The 30-day message volume is up 2,100%.&nbsp;Retail sentiment toward the stock was ‘extremely bullish’ as of early Wednesday, and it has mainly remained upbeat throughout the year. A bullish&nbsp;<a href="https://stocktwits.com/jeremy0916/message/639921688">watcher</a> has already set his sights on the $230 level for a stock that ended Tuesday’s session at $138.35.<figure class="image"><img style="aspect-ratio:724/433;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_3_01_43_AM_png_3c8d4a0547.webp" alt="Screenshot 2025-12-24 at 3.01.43 AM.png" width="724" height="433"></figure><h2 class="st-heading-2">Key Catalysts Investors Are Watching</h2>Fresh off its addition to the Nasdaq Biotechnology Index, Abivax is entering a catalyst-rich phase. The topline results from an ongoing 44-week maintenance trial, dubbed ABTECT-107, are expected to be read out in the second quarter of 2026. The company also plans to release topline data from the Phase 2 Crohn’s Disease study in the second half of next year.<h2 class="st-heading-2">Why Lilly Might Be Interested</h2>Obefazumod could be a better fit in Lilly’s immunology franchise, which includes Omvoh, an IL-23 inhibitor, used as a second-line treatment for adults with moderately to severely active UC and Crohn’s disease. It is administered as an IV infusion. Lilly also acquired Morphic Pharma, thereby adding an oral integrin blocker for UC.Abivax’s current market valuation is roughly $11 billion. The company’s cash position as of Sept. 2025 is 589.7 million euros, and the company said it has a cash runway into the fourth quarter of 2027.&nbsp;Whether that Lilly deal materializes or not, Abivax enters 2026 with elevated expectations, higher stakes, and far more eyes on the name than ever before.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-s-worst-year-in-four-decades-may-end-thanks-to-a-weight-loss-pill/cLepFr2REuw">Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill</a>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen.

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Equity

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.


ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above 50 Day Moving Average - What's Next...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above 50 Day Moving Average - Time to Sell...

Current Price	$82.12
Prev Close	$81.77
Open	$81.51
Dividend Yield	N/A
50-Day Moving Average	$83.11
Beta	N/A
Avg. Volume	12,157.32
PE Ratio	N/A

52-Week High	$90.91
52-Week Low	$33.78
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Latest BIB News

BIBProShares Ultra Nasdaq Biotechnology